Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives Average Rating of “Buy” from Brokerages

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last year is $25.60.

A number of research firms have weighed in on ATNM. Stephens began coverage on Actinium Pharmaceuticals in a report on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 target price on the stock. Maxim Group raised their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, May 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, June 17th.

Actinium Pharmaceuticals Stock Performance

ATNM stock opened at $7.76 on Wednesday. Actinium Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $10.24. The stock has a market capitalization of $231.09 million, a price-to-earnings ratio of -4.54 and a beta of 0.20.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. On average, equities analysts predict that Actinium Pharmaceuticals will post -1.57 earnings per share for the current year.

Institutional Trading of Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC raised its stake in Actinium Pharmaceuticals by 319.2% during the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock valued at $642,000 after purchasing an additional 62,459 shares during the period. Vanguard Group Inc. grew its holdings in Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock valued at $11,325,000 after buying an additional 82,113 shares in the last quarter. Sanders Morris Harris LLC purchased a new position in Actinium Pharmaceuticals during the 1st quarter valued at approximately $78,000. Finally, Creative Financial Designs Inc. ADV grew its holdings in Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 3,175 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.